The dream we all share is for future HCV therapy to be successful without interferon and ribavirin. We can only hope the extremely brutal 48-week regime of peginterferon and ribavirin ; "which only cured about 40 percent to 50 percent of people with genotype 1", will soon be considered the dinosaur of HCV therapy, and with that, die out. The promise of shorter treatment duration is upon us, however, because the virus becomes rapidly resistant to telaprevir it will be used in combination with SOC (peginterferon and ribavirin). The dream of treating without SOC will have to wait. I am grateful we will soon have telaprevir in our arsenal; with the drugs ability to achieve a higher cure rate *SVR across all genotypes.
Quoted From Vertex ;
REALIZE is the only Phase 3 study to date of a direct-acting antiviral medicine to include all three major subgroups of people with hepatitis C who did not achieve a viral cure with a previous course of therapy:
• Relapser: defined as a person whose hepatitis C virus was undetectable at the completion of at least 42 weeks of a prior course of therapy but whose virus became detectable during the follow-up period;
• Partial Responder: defined as a person who achieved at least a 2 log10 (100 times) reduction in viral load (HCV RNA) at week 12, but whose hepatitis C virus never became undetectable by week 24 of a prior course of therapy
• Null Responder: defined as a person who experienced a less than 2 log10 drop in viral load at week 12 of a prior course of therapy.
Pivotal study in 662 people who did not achieve a viral cure with previous therapy.
65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy.
The links provided below give a comprehensive overview of both Telaprevir and Boceprevir with a summary of other HCV oral inhibitors.
Treatment of Hepatitis C in 2011
Hepatitis C Treatment : Boceprevir In Non-responders
Hepatitis C: Protease Pipeline
2010/Telaprevir/Boceprevir SVR all Trials *geno 1,2,3
"The Best of The Liver Meeting® State-of-the-Art-Lectures"
AASLD 2010 Summary Of Hepatitis C Oral Inhibitors
In case you missed it:
Watch The Video
A New Era of Hepatitis C Therapy: AASLD 2010
This coming new year will change the way we treat HCV. If you are interested in using these new agents now is the time to find the right doctor and start the process.
Please take the time to read this folks : Hepatitis C New Drugs:Telaprevir,Boceprevir Potential for Misuse Is ‘Huge’
The buzz is telaprevir should be available in the U.S. by spring and recently telaprevir was submitted to Europe.
.
What Happened In 2010?
HIV and Hepatitis Top Ten For 2010 .
.
From The Advocate
Top Ten News Stories about Hepatitis B—
read about the news items that Christine Kukka, HBV Project Manager, ranked as the top news stories about HBV in 2010. . We would like to hear from our web site audience about what they believe are the top stories—take a very brief one page survey.
.
Newsletter: January 2011
HCV Advocate Top 10 News Items of 2010
A compilation of what we believed were the top ten stories of 2010. We judged telaprevir and boceprevir as the number one new story(s) of 2010, but the other items are in no particular order. We would like to hear from our web site audience about what they believe are the top stories—take a very brief one page survey .
.
In This Issue Of The HCV Advocate Newsletter:
Alan Franciscus, Editor-in-Chief
HealthWise: Vitamin D and the Liver
Lucinda K. Porter, RN
Lucinda K. Porter, RN
Alan Franciscus, Editor-in-Chief
.
No comments:
Post a Comment